# Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

> **NCT01039805** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 34 (actual)

## Conditions studied

- Gastroparesis

## Interventions

- **DRUG:** GSK962040 (50 mg)
- **DRUG:** Placebo
- **DRUG:** GSK962040 (75 mg)

## Key facts

- **NCT ID:** NCT01039805
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01039805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01039805, "Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01039805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*